Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Sells $20,368.40 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi sold 3,917 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.20, for a total value of $20,368.40. Following the completion of the transaction, the chief executive officer now owns 137,083 shares of the company’s stock, valued at $712,831.60. The trade was a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Y-mAbs Therapeutics Stock Up 3.8 %

Shares of NASDAQ:YMAB traded up $0.18 during midday trading on Tuesday, hitting $4.94. 338,078 shares of the stock traded hands, compared to its average volume of 467,358. The stock has a market capitalization of $223.38 million, a PE ratio of -9.15 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a one year low of $4.25 and a one year high of $17.78. The business’s 50 day moving average is $6.22 and its two-hundred day moving average is $10.38.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the business posted ($0.02) EPS. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares during the period. Barclays PLC boosted its stake in shares of Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after purchasing an additional 56,244 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares during the period. Intech Investment Management LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. Finally, Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Wall Street Analyst Weigh In

YMAB has been the subject of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Bank of America cut their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Finally, Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.